This item is covered by health insurance.

Quick order this pump through Insurance

Affordable valved holding chamber that minimizes the technique and coordination needed for effective inhaler treatments.

The PARI VORTEX® is an affordable valved holding chamber that minimizes the technique and coordination needed for effective inhaler treatments. Designed with non-electrostatic technology, VORTEX® delivers 56% more respirable particles compared to traditional plastic holding chambers and spacers.1 Now patients of all ages are assured a more efficient and consistent medication dose from their MDI, resulting in optimal treatments and a better quality of life.

Configurations

Configuration Part # NDC # HCPCS #
VORTEX® Valved Holding Chamber 051F7000 83490-0510-35 A4627
VORTEX® with Chloe Ladybug 051F7100 83490-0510-37 A4627
VORTEX® with Felix Frog 051F7200 83490-0510-39 A4627

1Zuberhuhler P, et al. In vitro testing of new non-electrostatic holding chamber with hydrofluoralkane salbutamol and beclomethasone inhalers. CHEST 2002; 122:185S.
2Wildhaber JH, et al. Effects of electrostatic charge, flow delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants. Thorax 1996; 51:985-988.

The Difference is in the Delivery1

VORTEX significantly reduces oropharyngeal deposition, which may cause unwanted side effects, vs. MDI alone.

Throat Deposition Graph

VORTEX delivers a higher respirable drug dose than MDI alone and OptiChamber Diamond.

Fine Particle Dose Graph

1Measurements according to Ph. Eur. 2.9.18 and USP 601: Next Generation Impactor; const. flow 30l/min; 50 ± 5 % relative humidity and 23 ± 2 °C: 3 test devices each measured in triplicates (n=3×3=9); pMDI Sultanol® (100μg Salbutamol, GlaxoSmithKline);
* All registered marks and trademarks belong to their respective companies